Table 6 Intra-group and inter-group pathological characteristics of EAOC and non-EAOC patients(n, %)

FIGO stage

 I/II

21

30

37

26

0.116^a/0.767^b/0.792^c

 III/IV

14

9

28

9

Differentiation

 Low

11

7

18

3

0.177^a/0.695^b/0.239^c

 Middle

17

17

40

12

 High

7

15

7

20

Biomarker

 ER(+)

25

7

49

3

< 0.01 ^a/0.667^b/0.311^c

 PR(+)

21

3

40

5

< 0.01 ^a/0.880^b/0.635^c

 P53(+)

29

30

43

25

0.526^a/0.076^b/0.589^c

 P16(+)

16

25

32

22

0.112^a/0.710^b/0.912^c

 MMR(-)

8

11

22

15

0.072^a/0.548^b/0.291^c

 Ki67(%)

29.1 ± 20

30.7 ± 14

29.6 ± 19

33.0 ± 16.5

0.718^a/0.907^b/0.564^c

 Napsin A(+)

7

11

11

26

< 0.01 ^a/0.459^b/0.230^c

 HNF-1β(+)

3

12

3

28

< 0.01 ^a/0.317^b/0.273^c